Zhao Xianlin, Huang Wei, Li Juan, Liu Yiling, Wan Meihua, Xue Guijun, Zhu Shifeng, Guo Hui, Xia Qing, Tang Wenfu
From the *Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Center, West China Hospital, Sichuan University, Chengdu, China; and †NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, United Kingdom.
Pancreas. 2016 Jan;45(1):58-63. doi: 10.1097/MPA.0000000000000377.
Noninvasive positive-pressure ventilation (NPPV) in acute respiratory distress syndrome (ARDS) is controversial. We aimed to assess the efficacy of NPPV on ARDS in acute pancreatitis (AP).
In this retrospective, single-center cohort study, demographic data, clinical and biochemical parameters of AP and developed ARDS on admission as well as before and after use of NPPV, and clinical outcomes were retrieved from the medical record database. Degrees of ARDS at presentation were retrospectively classified using the Berlin Definition.
Of 379 patients identified, 127 were eligible for inclusion and had NPPV for more than 24 hours. There were 44 mild, 64 moderate, and 19 severe patients with ARDS at presentation; endotracheal intubation rates were 0% (0/44), 23.4% (15/64), and 47.4% (9/19); and the mortality rates were 0% (0/44), 9.4% (6/64), and 15.8% (3/19), respectively. After NPPV treatment, systolic pressure, heart rate, respiratory rate, and fraction of inspired oxygen decreased, whereas oxygen saturation increased significantly in the NPPV success group compared with the failed group. Similar findings were also observed between survivors and nonsurvivors.
Noninvasive positive-pressure ventilation may be an effective option for the initial treatment of ARDS patients in AP, but the use of NPPV should be applied prudently in the most severe cases.
急性呼吸窘迫综合征(ARDS)患者使用无创正压通气(NPPV)存在争议。我们旨在评估NPPV对急性胰腺炎(AP)合并ARDS的疗效。
在这项回顾性单中心队列研究中,从病历数据库中检索了AP患者及确诊ARDS患者入院时、使用NPPV前后的人口统计学数据、临床和生化参数以及临床结局。采用柏林定义对ARDS发病时的严重程度进行回顾性分类。
在379例确诊患者中,127例符合纳入标准且使用NPPV超过24小时。ARDS发病时,44例为轻度、64例为中度、19例为重度;气管插管率分别为0%(0/44)、23.4%(15/64)和47.4%(9/19);死亡率分别为0%(0/44)、9.4%(6/64)和15.8%(3/19)。NPPV治疗后,NPPV成功组的收缩压、心率、呼吸频率和吸入氧分数降低,而氧饱和度显著升高,失败组则不然。幸存者和非幸存者之间也观察到类似结果。
无创正压通气可能是AP合并ARDS患者初始治疗的有效选择,但在最严重的病例中应谨慎使用NPPV。